Hydralazine

• UNSPSC Description:

  Hydralazine is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine has antioxidant activity, as well as inhibits reactive oxygen species (ROS) release and O2·- generation with an IC50 value of 9.53 mM and 1.19 mM, respectively[1][2].

• Target Antigen:

  Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hydralazine.html

• Solubility:

  10 mM in DMSO

• Smiles:

  N/N=C1NN=CC2=C\1C=CC=C2

• Molecular Weight:

  160.18

• References & Citations:

  [1]Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006 Feb 28;4:10.|[2]Leiro JM, et al. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol. 2004 Feb;4(2):163-77.J Pharm Anal. 2023 Aug 11.|Neurosci Bull. 2020 Oct;36(10):1158-1170.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  86-54-4